Literature DB >> 11063648

HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients.

M R Brown1, A Noffsinger, M R First, I Penn, N Husseinzadeh.   

Abstract

OBJECTIVE: Immunocompromised patients, such as female renal transplant recipients, have an increased incidence of neoplasms involving the lower genital tract (i.e., cervix, vagina, vulva). The relationship between lower genital tract neoplasms and human papillomavirus (HPV) infection has been established and high-risk oncogenic subtypes have been identified (HPV 16, 18, 45, and 56). The purpose of this study is to evaluate HPV subtypes present in lower genital tract neoplasms of post renal transplant women and compare HPV subtypes found in these patients with immunocompetent patients having similar neoplasms and normal immunocompetent controls.
METHODS: Twenty specimens from lower genital tract neoplasms of 16 renal transplant patients, 13 specimens from 13 immunocompetent patients with similar histology, and 13 patients with normal lower genital tract histology were analyzed for the presence of HPV using polymerase chain reaction. HPV primers including the L1 (late) region consensus primers and primers specific for the HPV E6 (early) region for subtypes 6, 11, 16, and 18 were amplified with DNA from the above patient samples.
RESULTS: Overall, HPV was detected in 21/46 specimens tested. Thirteen of the HPV-positive specimens were from transplant patients, and 8 were from immunocompetent patients (5 immunocompetent with disease and 3 normal patients). This difference in the total number of HPV-positive cases was statistically significant between the transplant and immunocompetent group (P = 0.02). Although no difference in HPV 6 and/or 11 was detected between the two groups, HPV subtypes 16 and/or 18 approached statistical significant difference (P = 0.06).
CONCLUSIONS: High-risk oncogenic HPV subtypes 16 and/or 18 were found at a higher rate in transplant patients compared with their immunocompetent counterparts. The combination of immunocompromise and increased HPV 16 and/or 18 positivity may place these patients at increased risk for aggressive lower genital tract neoplastic progression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063648     DOI: 10.1006/gyno.2000.5942

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients.

Authors:  Sung Taek Park; Min Jong Song; Jong Sup Park; Soo Young Hur; Chung Won Lee
Journal:  World J Surg Oncol       Date:  2011-07-13       Impact factor: 2.754

2.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

3.  Pediatric vulvar squamous cell carcinoma in a liver transplantation recipient: a case report.

Authors:  Na-Rae Kim; Soyi Lim; Hyun Yee Cho
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

4.  Human Papillomavirus (HPV) DNA Detection Using Self-Sampling Devices in Women Undergoing Long Term Immunosuppressive Therapy.

Authors:  Aleksandra Wielgos; Bronislawa Pietrzak; Mariusz Sikora; Gajane Martirosian; Barbara Suchonska; Jolanta Gozdowska; Urszula Oldakowska-Jedynak; Zoulikha Jabiry-Zieniewicz; Magdalena Durlik; Lidia Rudnicka; Miroslaw Wielgos
Journal:  Viruses       Date:  2020-08-30       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.